What is Braftovi used to treat?
Braftovi is used in combination with other drugs to treat patients with advanced melanoma, advanced non-small cell lung cancer (NSCLC) and advanced colorectal cancer with BRAF gene mutations.
Braftovi is an oral small molecule BRAF kinase inhibitor.
Melanoma
Braftovi (encorafenib) is used in combination with Mektovi (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Roughly 50% of patients diagnosed with metastatic melanoma test positive for the BRAF mutation, and it is the most common genetic mutation in metastatic melanoma.
Braftovi is not indicated for the treatment of patients with wild-type BRAF melanoma.
Colorectal Cancer
Braftovi is used in combination with Erbitux (cetuximab), for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
Braftovi is not indicated for treatment of patients with wild-type BRAF CRC.
BRAF mutations are estimated to occur in up to 15% of people with metastatic colorectal cancer.
Non-Small Cell Lung Cancer (NSCLC)
Braftovi is used in combination with Mektovi (binimetinib) to treat adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
BRAF mutations are estimated to occur in 2% to 5% of people with metastatic non-small cell lung cancer.
Braftovi is not indicated for the treatment of patients with wild-type BRAF NSCLC.
Related questions
References
- Braftovi (encorafenib) prescribing information. Revised 10/2023. Pfizer Inc. New York, NY. Accessed Oct 16, 2023 at https://labeling.pfizer.com/ShowLabeling.aspx?id=12990
Read next
What is the success rate of Keytruda?
In general, PD-1 immune checkpoint inhibitors like Keytruda have been shown to significantly prolong overall survival (OS) in some patients with various cancer types, but Keytruda does not always work for everyone. Continue reading
What is the difference between Opdivo and Keytruda?
Opdivo (nivolumab) and Keytruda (pembrolizumab) are two immunotherapy drugs for various cancers. Both are monoclonal antibodies, known as PD1 inhibitors, first approved in 2014. Opdivo is from Bristol Myers Squibb, and Keytruda is from Merck & Co. The main differences lie in dosing, combination therapies, and approved cancer types. Continue reading
Pembrolizumab vs. nivolumab: How do they compare?
Pembrolizumab and nivolumab are both prescription medications used to treat various types of cancers, including solid tumors and blood cancers. They may be used alone or in combination with other medicines for cancers that are more advanced, have spread in the body, or are no longer responding to previous treatments. Continue reading
Related medical questions
- What happens when you stop taking Opdivo for melanoma?
- Are there cost-saving programs for Tecentriq?
- Is atezolizumab (Tecentriq) a chemotherapy or immunotherapy drug?
- How effective is atezolizumab (Tecentriq)?
- Does atezolizumab (Tecentriq) cause hair loss?
- How is atezolizumab (Tecentriq) administered?
- Sunscreen Safety: What do you need to know?
- How often should I have a colonoscopy with ulcerative colitis?
- Why do you need to take Xeloda with food?
- How long does oxaliplatin stay in your system?
- How many cycles of oxaliplatin can you have?
- What is the difference between Mvasi and Avastin?
- How long does Lonsurf increase survival in colorectal cancer?
- How effective is tucatinib (Tukysa) for breast cancer?
- What's the mechanism of action for tucatinib?
- Common Types of Cancer Medications
- How do I know if Aldara is working for skin cancer?
- What type of drug is Libtayo?
- How does Odomzo work?
Drug information
Related support groups
- Braftovi (2 questions, 3 members)
- Encorafenib (2 questions, 3 members)
- Melanoma (18 questions, 50 members)
- Colorectal Cancer (16 questions, 52 members)
- Skin Cancer (12 questions, 38 members)
- Melanoma - Metastatic (5 questions, 30 members)